Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Reduced Thigh Pain with Short Femoral Stem Design Following Direct Anterior Primary Total Hip Arthroplasty.

Horwood NJ, Nam D, Greco NJ, Lombardi AV Jr, Clohisy JC, Lawrie CM, Berend KR.

Surg Technol Int. 2019 May 15;34:437-444.

PMID:
31037711
2.

Fully reduced HMGB1 accelerates the regeneration of multiple tissues by transitioning stem cells to GAlert.

Lee G, Espirito Santo AI, Zwingenberger S, Cai L, Vogl T, Feldmann M, Horwood NJ, Chan JK, Nanchahal J.

Proc Natl Acad Sci U S A. 2018 May 8;115(19):E4463-E4472. doi: 10.1073/pnas.1802893115. Epub 2018 Apr 19.

3.

Bruton's tyrosine kinase regulates TLR7/8-induced TNF transcription via nuclear factor-κB recruitment.

Page TH, Urbaniak AM, Espirito Santo AI, Danks L, Smallie T, Williams LM, Horwood NJ.

Biochem Biophys Res Commun. 2018 May 5;499(2):260-266. doi: 10.1016/j.bbrc.2018.03.140. Epub 2018 Mar 22.

4.

Strain dependent differences in glucocorticoid-induced bone loss between C57BL/6J and CD-1 mice.

Ersek A, Santo AI, Vattakuzhi Y, George S, Clark AR, Horwood NJ.

Sci Rep. 2016 Nov 4;6:36513. doi: 10.1038/srep36513.

5.

Macrophage Polarization and Bone Formation: A review.

Horwood NJ.

Clin Rev Allergy Immunol. 2016 Aug;51(1):79-86. doi: 10.1007/s12016-015-8519-2. Review.

PMID:
26498771
6.

Selective inhibition of TNFR1 reduces osteoclast numbers and is differentiated from anti-TNF in a LPS-driven model of inflammatory bone loss.

Espirito Santo AI, Ersek A, Freidin A, Feldmann M, Stoop AA, Horwood NJ.

Biochem Biophys Res Commun. 2015 Sep 4;464(4):1145-1150. doi: 10.1016/j.bbrc.2015.07.094. Epub 2015 Jul 22.

PMID:
26208457
7.

Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease.

Ersek A, Xu K, Antonopoulos A, Butters TD, Santo AE, Vattakuzhi Y, Williams LM, Goudevenou K, Danks L, Freidin A, Spanoudakis E, Parry S, Papaioannou M, Hatjiharissi E, Chaidos A, Alonzi DS, Twigg G, Hu M, Dwek RA, Haslam SM, Roberts I, Dell A, Rahemtulla A, Horwood NJ, Karadimitris A.

J Clin Invest. 2015 Jun;125(6):2279-92. doi: 10.1172/JCI59987. Epub 2015 Apr 27.

8.

Low-dose TNF augments fracture healing in normal and osteoporotic bone by up-regulating the innate immune response.

Chan JK, Glass GE, Ersek A, Freidin A, Williams GA, Gowers K, Espirito Santo AI, Jeffery R, Otto WR, Poulsom R, Feldmann M, Rankin SM, Horwood NJ, Nanchahal J.

EMBO Mol Med. 2015 May;7(5):547-61. doi: 10.15252/emmm.201404487.

9.

OX40L blockade is therapeutic in arthritis, despite promoting osteoclastogenesis.

Gwyer Findlay E, Danks L, Madden J, Cavanagh MM, McNamee K, McCann F, Snelgrove RJ, Shaw S, Feldmann M, Taylor PC, Horwood NJ, Hussell T.

Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):2289-94. doi: 10.1073/pnas.1321071111. Epub 2014 Jan 27.

10.

Potential of human fetal chorionic stem cells for the treatment of osteogenesis imperfecta.

Jones GN, Moschidou D, Abdulrazzak H, Kalirai BS, Vanleene M, Osatis S, Shefelbine SJ, Horwood NJ, Marenzana M, De Coppi P, Bassett JH, Williams GR, Fisk NM, Guillot PV.

Stem Cells Dev. 2014 Feb 1;23(3):262-76. doi: 10.1089/scd.2013.0132. Epub 2013 Oct 16.

11.

Immune cells and bone: coupling goes both ways.

Horwood NJ.

Immunol Invest. 2013;42(7):532-43. doi: 10.3109/08820139.2013.822762. Review.

PMID:
24004057
12.

Cells of the immune system orchestrate changes in bone cell function.

Wythe SE, Nicolaidou V, Horwood NJ.

Calcif Tissue Int. 2014 Jan;94(1):98-111. doi: 10.1007/s00223-013-9764-0. Epub 2013 Aug 3. Review.

PMID:
23912951
13.

Effect of glycosphingolipids on osteoclastogenesis and osteolytic bone diseases.

Ersek A, Karadimitris A, Horwood NJ.

Front Endocrinol (Lausanne). 2012 Aug 23;3:106. doi: 10.3389/fendo.2012.00106. eCollection 2012.

14.

Monocytes induce STAT3 activation in human mesenchymal stem cells to promote osteoblast formation.

Nicolaidou V, Wong MM, Redpath AN, Ersek A, Baban DF, Williams LM, Cope AP, Horwood NJ.

PLoS One. 2012;7(7):e39871. doi: 10.1371/journal.pone.0039871. Epub 2012 Jul 3.

15.

Tec family kinases in inflammation and disease.

Horwood NJ, Urbaniak AM, Danks L.

Int Rev Immunol. 2012 Apr;31(2):87-103. doi: 10.3109/08830185.2012.670334. Review.

PMID:
22449071
16.

Dual-specificity phosphatase 1-null mice exhibit spontaneous osteolytic disease and enhanced inflammatory osteolysis in experimental arthritis.

Vattakuzhi Y, Abraham SM, Freidin A, Clark AR, Horwood NJ.

Arthritis Rheum. 2012 Jul;64(7):2201-10. doi: 10.1002/art.34403.

17.

Hck tyrosine kinase regulates TLR4-induced TNF and IL-6 production via AP-1.

Smolinska MJ, Page TH, Urbaniak AM, Mutch BE, Horwood NJ.

J Immunol. 2011 Dec 1;187(11):6043-51. doi: 10.4049/jimmunol.1100967. Epub 2011 Oct 21.

18.

Th17 cells, not IL-17+ γδ T cells, drive arthritic bone destruction in mice and humans.

Pöllinger B, Junt T, Metzler B, Walker UA, Tyndall A, Allard C, Bay S, Keller R, Raulf F, Di Padova F, O'Reilly T, Horwood NJ, Patel DD, Littlewood-Evans A.

J Immunol. 2011 Feb 15;186(4):2602-12. doi: 10.4049/jimmunol.1003370. Epub 2011 Jan 7.

19.

TNF-alpha promotes fracture repair by augmenting the recruitment and differentiation of muscle-derived stromal cells.

Glass GE, Chan JK, Freidin A, Feldmann M, Horwood NJ, Nanchahal J.

Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1585-90. doi: 10.1073/pnas.1018501108. Epub 2011 Jan 5.

20.

Inhibition of osteoclast function reduces hematopoietic stem cell numbers in vivo.

Lymperi S, Ersek A, Ferraro F, Dazzi F, Horwood NJ.

Blood. 2011 Feb 3;117(5):1540-9. doi: 10.1182/blood-2010-05-282855. Epub 2010 Dec 3.

21.

IL-10 inhibits transcription elongation of the human TNF gene in primary macrophages.

Smallie T, Ricchetti G, Horwood NJ, Feldmann M, Clark AR, Williams LM.

J Exp Med. 2010 Sep 27;207(10):2081-8. doi: 10.1084/jem.20100414. Epub 2010 Aug 30.

22.

Elevated cytokine production restores bone resorption by human Btk-deficient osteoclasts.

Danks L, Workman S, Webster D, Horwood NJ.

J Bone Miner Res. 2011 Jan;26(1):182-92. doi: 10.1002/jbmr.210.

23.

TGF-beta coordinately activates TAK1/MEK/AKT/NFkB and SMAD pathways to promote osteoclast survival.

Gingery A, Bradley EW, Pederson L, Ruan M, Horwood NJ, Oursler MJ.

Exp Cell Res. 2008 Sep 10;314(15):2725-38. doi: 10.1016/j.yexcr.2008.06.006. Epub 2008 Jun 13.

24.

Bmx regulates LPS-induced IL-6 and VEGF production via mRNA stability in rheumatoid synovial fibroblasts.

Palmer CD, Mutch BE, Page TH, Horwood NJ, Foxwell BM.

Biochem Biophys Res Commun. 2008 Jun 13;370(4):599-602. doi: 10.1016/j.bbrc.2008.03.142. Epub 2008 Apr 8.

PMID:
18402776
25.

Bmx tyrosine kinase regulates TLR4-induced IL-6 production in human macrophages independently of p38 MAPK and NFkapp}B activity.

Palmer CD, Mutch BE, Workman S, McDaid JP, Horwood NJ, Foxwell BM.

Blood. 2008 Feb 15;111(4):1781-8. Epub 2007 Nov 19.

26.

Potential of mesenchymal stem cell therapy.

Dazzi F, Horwood NJ.

Curr Opin Oncol. 2007 Nov;19(6):650-5. Review.

PMID:
17906466
27.

Chemical inhibition of Src family kinases affects major LPS-activated pathways in primary human macrophages.

Smolinska MJ, Horwood NJ, Page TH, Smallie T, Foxwell BM.

Mol Immunol. 2008 Feb;45(4):990-1000. Epub 2007 Sep 17.

PMID:
17875324
28.

Bruton's tyrosine kinase is required for TLR2 and TLR4-induced TNF, but not IL-6, production.

Horwood NJ, Page TH, McDaid JP, Palmer CD, Campbell J, Mahon T, Brennan FM, Webster D, Foxwell BM.

J Immunol. 2006 Mar 15;176(6):3635-41.

29.

A novel mechanism for TNF-alpha regulation by p38 MAPK: involvement of NF-kappa B with implications for therapy in rheumatoid arthritis.

Campbell J, Ciesielski CJ, Hunt AE, Horwood NJ, Beech JT, Hayes LA, Denys A, Feldmann M, Brennan FM, Foxwell BM.

J Immunol. 2004 Dec 1;173(11):6928-37.

30.

Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation.

Häusler KD, Horwood NJ, Chuman Y, Fisher JL, Ellis J, Martin TJ, Rubin JS, Gillespie MT.

J Bone Miner Res. 2004 Nov;19(11):1873-81. Epub 2004 Aug 16.

31.

T-cells mediate an inhibitory effect of interleukin-4 on osteoclastogenesis.

Mirosavljevic D, Quinn JM, Elliott J, Horwood NJ, Martin TJ, Gillespie MT.

J Bone Miner Res. 2003 Jun;18(6):984-93.

32.

Bruton's tyrosine kinase is required for lipopolysaccharide-induced tumor necrosis factor alpha production.

Horwood NJ, Mahon T, McDaid JP, Campbell J, Mano H, Brennan FM, Webster D, Foxwell BM.

J Exp Med. 2003 Jun 16;197(12):1603-11.

33.

Interleukin-18 is a novel mitogen of osteogenic and chondrogenic cells.

Cornish J, Gillespie MT, Callon KE, Horwood NJ, Moseley JM, Reid IR.

Endocrinology. 2003 Apr;144(4):1194-201.

PMID:
12639900
34.

Is NF-kappaB a useful therapeutic target in rheumatoid arthritis?

Feldmann M, Andreakos E, Smith C, Bondeson J, Yoshimura S, Kiriakidis S, Monaco C, Gasparini C, Sacre S, Lundberg A, Paleolog E, Horwood NJ, Brennan FM, Foxwell BM.

Ann Rheum Dis. 2002 Nov;61 Suppl 2:ii13-8. Review.

35.

High-efficiency gene transfer into nontransformed cells: utility for studying gene regulation and analysis of potential therapeutic targets.

Horwood NJ, Smith C, Andreakos E, Quattrocchi E, Brennan FM, Feldmann M, Foxwell BM.

Arthritis Res. 2002;4 Suppl 3:S215-25. Epub 2002 May 9. Review.

36.

IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro.

Horwood NJ, Elliott J, Martin TJ, Gillespie MT.

J Immunol. 2001 Apr 15;166(8):4915-21.

37.

Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.

Quinn JM, Horwood NJ, Elliott J, Gillespie MT, Martin TJ.

J Bone Miner Res. 2000 Aug;15(8):1459-66.

38.

Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues.

Kartsogiannis V, Zhou H, Horwood NJ, Thomas RJ, Hards DK, Quinn JM, Niforas P, Ng KW, Martin TJ, Gillespie MT.

Bone. 1999 Nov;25(5):525-34.

PMID:
10574572
39.

Activated T lymphocytes support osteoclast formation in vitro.

Horwood NJ, Kartsogiannis V, Quinn JM, Romas E, Martin TJ, Gillespie MT.

Biochem Biophys Res Commun. 1999 Nov;265(1):144-50.

PMID:
10548505
40.

Breast cancer cells interact with osteoblasts to support osteoclast formation.

Thomas RJ, Guise TA, Yin JJ, Elliott J, Horwood NJ, Martin TJ, Gillespie MT.

Endocrinology. 1999 Oct;140(10):4451-8.

PMID:
10499498
41.

Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells.

Horwood NJ, Elliott J, Martin TJ, Gillespie MT.

Endocrinology. 1998 Nov;139(11):4743-6.

PMID:
9794488
42.

Interleukin-18: perspectives on the newest interleukin.

Gillespie MT, Horwood NJ.

Cytokine Growth Factor Rev. 1998 Jun;9(2):109-16. Review.

PMID:
9754705
43.

Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor.

Horwood NJ, Udagawa N, Elliott J, Grail D, Okamura H, Kurimoto M, Dunn AR, Martin T, Gillespie MT.

J Clin Invest. 1998 Feb 1;101(3):595-603.

44.

Interleukin-18 (interferon-gamma-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-gamma to inhibit osteoclast formation.

Udagawa N, Horwood NJ, Elliott J, Mackay A, Owens J, Okamura H, Kurimoto M, Chambers TJ, Martin TJ, Gillespie MT.

J Exp Med. 1997 Mar 17;185(6):1005-12.

Supplemental Content

Loading ...
Support Center